Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00054496
- Lead Sponsor
- The Cleveland Clinic
- Brief Summary
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
- Detailed Description
OBJECTIVES:
* Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib.
* Determine the progression-free and overall survival of patients treated with this drug.
OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 73
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling Efficacy of tumor EGFR amplification in predicting response to treatment Progression-free survival
Trial Locations
- Locations (1)
Cleveland Clinic Taussig Cancer Center
🇺🇸Cleveland, Ohio, United States